| Cancer-related Molecular Pathways | Lifetime | 47 | NL 1 | 99.72 |
| Ubiquitin and proteasome pathways | Lifetime | 53 | NL 1 | 99.60 |
| Virus-based gene therapy research | Lifetime | 183 | NL 4 | 99.29 |
| Protein Degradation and Inhibitors | Lifetime | 74 | NL 2 | 99.30 |
| Cancer Genomics and Diagnostics | Lifetime | 420 | NL 13 | 99.20 |
| Histone Deacetylase Inhibitors Research | Lifetime | 152 | NL 2 | 98.38 |
| Melanoma and MAPK Pathways | Lifetime | 121 | NL 4 | 98.54 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 215 | NL 5 | 98.10 |
| Telomeres, Telomerase, and Senescence | Lifetime | 111 | NL 5 | 97.29 |
| interferon and immune responses | Lifetime | 345 | NL 2 | 97.68 |
| Colorectal Cancer Treatments and Studies | Lifetime | 491 | NL 21 | 98.52 |
| CRISPR and Genetic Engineering | Lifetime | 757 | NL 23 | 97.56 |
| Neuroblastoma Research and Treatments | Lifetime | 484 | NL 17 | 97.48 |
| Cancer Research and Treatments | Lifetime | 768 | NL 11 | 96.49 |
| HER2/EGFR in Cancer Research | Lifetime | 596 | NL 14 | 97.60 |
| Viral Infectious Diseases and Gene Expression in Insects | Lifetime | 610 | NL 14 | 96.15 |
| Cancer Mechanisms and Therapy | Lifetime | 613 | NL 7 | 94.27 |
| Retinoids in leukemia and cellular processes | Lifetime | 717 | NL 14 | 94.89 |
| Microtubule and mitosis dynamics | Lifetime | 964 | NL 18 | 94.73 |
| Ocular Oncology and Treatments | Lifetime | 452 | NL 19 | 94.00 |
| Chromatin Remodeling and Cancer | Lifetime | 925 | NL 17 | 83.20 |
| Ubiquitin and proteasome pathways | 2021-2025 | 199 | NL 4 | 92.64 |
| Telomeres, Telomerase, and Senescence | 2021-2025 | 71 | NL 3 | 92.74 |
| Histone Deacetylase Inhibitors Research | 2021-2025 | 240 | NL 3 | 89.71 |
| Cancer-related Molecular Pathways | 2021-2025 | 228 | NL 1 | 89.31 |
| Protein Degradation and Inhibitors | 2021-2025 | 524 | NL 6 | 90.34 |
| Cancer Mechanisms and Therapy | 2021-2025 | 607 | NL 1 | 77.80 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 530 | NL 10 | 69.55 |
| Microtubule and mitosis dynamics | 2021-2025 | 728 | NL 21 | 69.98 |